Abedi M R, Bäckman L, Boström L, Lindbäck B, Ringdén O
Department of Clinical Immunology, Huddinge Hospital, Karolinska Institute, Stockholm, Sweden.
Bone Marrow Transplant. 1990 Aug;6(2):121-6.
Serum erythropoietin (EPO) levels were measured by radioimmunoassay in 36 patients undergoing allogeneic bone marrow transplantation (BMT). Serum EPO levels before conditioning treatment for BMT were generally higher than the levels obtained from healthy controls (49 +/- 17 (SEM) and 17 +/- 0.6, respectively). One day prior to BMT, after conditioning by chemotherapy with or without total body irradiation, the mean EPO level was markedly elevated (218 +/- 23 U/l, p less than 0.001) and reached to its highest level at 1 week post-BMT (269 +/- 40 U/l). Although, the EPO levels were significantly lower at 1 month (98 +/- 24 U/l, p less than 0.001), they were still elevated up to 3 months post-BMT, after which they gradually normalized. Patients given methotrexate and cyclosporine for prophylaxis against graft-versus-host disease (GVHD) had significantly lower EPO levels during the first 3 months post-BMT than patients transplanted with T cell-depleted marrow (p less than 0.05). Patients with post-transplant nephrotoxicity had lower, though not statistically significant, EPO levels than patients with normal renal function (p = 0.07). Acute GVHD and number of blood transfusions had no influence on serum EPO levels after BMT.
采用放射免疫分析法对36例接受异基因骨髓移植（BMT）的患者进行血清促红细胞生成素（EPO）水平检测。BMT预处理前的血清EPO水平通常高于健康对照者（分别为49±17（SEM）和17±0.6）。在BMT前一天，经化疗联合或不联合全身照射预处理后，EPO平均水平显著升高（218±23 U/l，p<0.001），并在BMT后1周达到最高水平（269±40 U/l）。尽管在1个月时EPO水平显著降低（98±24 U/l，p<0.001），但在BMT后3个月内仍处于升高状态，此后逐渐恢复正常。接受甲氨蝶呤和环孢素预防移植物抗宿主病（GVHD）的患者在BMT后的前3个月内EPO水平显著低于接受T细胞去除骨髓移植的患者（p<0.05）。移植后出现肾毒性的患者EPO水平低于肾功能正常的患者，尽管差异无统计学意义（p = 0.07）。急性GVHD和输血次数对BMT后的血清EPO水平无影响。
